*University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; †Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and ‡School of Information Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania.
Inflamm Bowel Dis. 2017 Dec;23(12):2180-2188. doi: 10.1097/MIB.0000000000001251.
Patients with inflammatory bowel disease are at an increased risk of Clostridium difficile infection (CDI), but the impact of CDI on disease severity is unclear. The aim of this study was to determine the effect of CDI on long-term disease outcome in a matched cohort of patients with inflammatory bowel disease.
Patients who tested positive for infection formed the CDI-positive group. We generated a 1:2 propensity matched case to control cohort based on risk factors for CDI in the year before infection. Health care utilization data (emergency department use, hospitalizations, and telephone encounters), medications, laboratories, disease activity, and quality-of-life metrics were compared by CDI status.
A total of 198 patients (66 CDI and 132 matched controls) were included (56.6% women; 60.1% Crohn's disease, and 39.9% ulcerative colitis). In the year of infection, having CDI was significantly associated with more steroid and antibiotic exposure, elevated C-reactive protein or erythrocyte sedimentation rate, low vitamin D, increased disease activity, worse quality of life, and increased health care utilization (all P < 0.01). During the next year after infection, patients with CDI continued to have increased exposure to CDI-targeted antibiotics (P < 0.001) and other antibiotics (P = 0.02). They also continued to have more clinic visits (P = 0.02), telephone encounters (P = 0.001), and increased health care financial charges (P = 0.001).
CDI in inflammatory bowel disease is significantly associated with markers of disease severity, increased health care utilization and poor quality of life during the year of infection, and a 5-fold increase in health care charges in the year after infection (see Video Abstract, Supplemental Digital Content, http://links.lww.com/IBD/B658).
炎症性肠病患者发生艰难梭菌感染(CDI)的风险增加,但 CDI 对疾病严重程度的影响尚不清楚。本研究旨在确定 CDI 对炎症性肠病患者匹配队列长期疾病结局的影响。
检测到感染的患者形成 CDI 阳性组。我们根据感染前一年 CDI 的危险因素,生成了 1:2 的倾向匹配病例对照队列。通过 CDI 状态比较医疗保健利用数据(急诊使用、住院和电话咨询)、药物、实验室、疾病活动度和生活质量指标。
共纳入 198 例患者(66 例 CDI 和 132 例匹配对照)(56.6%女性;60.1%克罗恩病,39.9%溃疡性结肠炎)。在感染当年,CDI 与更多的皮质类固醇和抗生素暴露、C 反应蛋白或红细胞沉降率升高、维生素 D 水平降低、疾病活动度增加、生活质量下降和医疗保健利用增加显著相关(均 P < 0.01)。在感染后的下一年,CDI 患者继续增加 CDI 靶向抗生素(P < 0.001)和其他抗生素(P = 0.02)的使用。他们也继续增加门诊就诊次数(P = 0.02)、电话咨询次数(P = 0.001)和医疗保健费用增加(P = 0.001)。
炎症性肠病中的 CDI 与感染当年疾病严重程度的标志物、医疗保健利用增加和生活质量下降显著相关,并且在感染后一年的医疗保健费用增加了 5 倍(详见视频摘要,补充数字内容,http://links.lww.com/IBD/B658)。